Celecoxib
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Celecoxib: From Rheumatoid Arthritis to Acromesomelic Dysplasia, Hunter-Thompson Type
One-Sentence Summary
Celecoxib is a COX-2-selective anti-inflammatory drug, originally used for arthritic conditions such as rheumatoid arthritis, ankylosing spondylitis and osteoarthritis. The TxGNN model ranks acromesomelic dysplasia, Hunter-Thompson type (a rare genetic skeletal disorder) as its top prediction, with a very high score. No clinical trials and no publications currently support this prediction, so it rests on the model output alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, juvenile idiopathic arthritis (from the knowledge-graph indication list, because the Singapore licence records contain no indication text) |
| Predicted New Indication | Acromesomelic dysplasia, Hunter-Thompson type |
| TxGNN Prediction Score | 99.88% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 14 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data is not available in the data compiled for this report. Celecoxib is known to be a selective COX-2 inhibitor. It reduces prostaglandin-driven inflammation and pain, and its efficacy in arthritic diseases is established.
Acromesomelic dysplasia, Hunter-Thompson type, is a rare skeletal dysplasia caused by a genetic defect in the CDMP1/GDF5 pathway. It is a developmental disorder, not an inflammatory one. COX-2 inhibition has no known effect on this pathway.
The high score most likely reflects the model's network proximity to musculoskeletal diseases rather than a real biological link. At best, celecoxib could offer symptomatic pain relief. There is no evidence it would change the course of the disease.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Singapore Market Information
Celecoxib has 14 valid single-ingredient registrations, all oral capsules and none cancelled. The licence records contain no approved-indication text. The five main authorizations are listed below.
| Authorization Number | Product Name | Dosage Form |
|---|---|---|
| SIN11240P | Celebrex Capsules 100 mg | Capsule |
| SIN11241P | Celebrex Capsules 200 mg | Capsule |
| SIN13653P | Celebrex Capsule 400 mg | Capsule |
| SIN14560P | Celecoxib Sandoz Capsule 200 mg | Capsule |
| SIN15754P | Hovid-Celecoxib Capsule 200 mg | Capsule |
Safety Considerations
Label-based warnings and contraindications were not available, so please refer to the package insert for them. The following information comes from other sources.
- Contraindication signals (knowledge graph, not label text):
- Cardiovascular: hypertension, congestive heart failure, myocardial infarction, stroke and cerebrovascular disorders, other cardiovascular and heart disease
- Gastrointestinal: peptic ulcer disease (including active)
- Kidney and liver disease
- Asthma (including allergic and intrinsic)
- Gallbladder disease
- Anaemia and haemoglobinopathy
- Substance abuse/dependence
- Drug Interactions: 100 interactions were recorded. The one rated Major is eliglustat. Many others are rated Moderate, including:
- Sulfonylureas and other antidiabetics: glimepiride, glipizide, glyburide, chlorpropamide, acetohexamide, nateglinide, metformin, exenatide
- Aminosalicylates: mesalazine, balsalazide, olsalazine
- Others: hydrocortisone, cimetidine, levofloxacin, metronidazole, naltrexone, kanamycin, fenfluramine
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has no clinical or literature support, and no plausible mechanism links COX-2 inhibition to a genetic skeletal dysplasia. Celecoxib also carries meaningful cardiovascular, gastrointestinal and renal risks, which are not justified without evidence of benefit.
To proceed, the following is needed:
- Biological evidence that prostaglandin or COX-2 pathways contribute to this disease (preclinical or mechanistic studies)
- Detailed mechanism-of-action data
- Package insert warnings and contraindications for the Singapore products
- A defined target population and outcome measure, if symptomatic pain relief is the goal
Note on other predictions for this drug: Among the other top-10 predictions, inflammatory spondylopathy (score 99.80%) has the strongest support. It has 11 registered trials, including two completed Phase 3 trials (NCT00648141, NCT00762463), and 20 publications, giving it evidence level L1. This largely overlaps with celecoxib's existing ankylosing spondylitis use, so it is closer to confirming a known use than to new repurposing. It would be worth evaluating separately, with cardiovascular, gastrointestinal and renal monitoring.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.